Shutting down cancer’s
most commonly mutated pathway—
to transform the
lives of millions

Erasca is a clinical-stage precision oncology company driven by a bold mission—to erase cancer. We are on a journey to shut down one of cancer’s most commonly mutated signaling cascades, the RAS/MAPK pathway, which affects approximately 5.5 million lives each year worldwide. Our promising pipeline targets the RAS/MAPK pathway at virtually every turn, endowing us with the potential to make a transformative difference in the treatment and lives of people suffering from a wide range of devastating cancers—bringing hope, where there was little, that the future can be brighter and cancer free.

Targeting theRAS/MAPK Pathway

Focused on cancer’s most commonly mutated pathway—affecting approximately 5.5 million lives globally per year

Advancing aRobust Pipeline

A modality-agnostic portfolio of therapeutic programs purposefully built to comprehensively shut down the RAS/MAPK pathway


Join a mission-driven company that believes serious cancer-fighting science can also be serious fun